Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Employees - 73000,
CEO - Robert Davis,
Sector - Healthcare,
Country - US,
Market Cap -
Altman ZScore(max is 10): 3.69, Piotroski Score(max is 10): 6, Working Capital: $8070000000, Total Assets: $128685000000, Retained Earnings: $66721000000, EBIT: 12673000000, Total Liabilities: $82754000000, Revenue: $65593000000
AryaFin Target Price - $124.96 - Current Price $ - Analyst Target Price $
| Ticker | MRK |
| Index | |
| Curent Price | |
| Change | |
| Market Cap | |
| Average Volume | |
| Income | |
| Sales | |
| Book Value/Share | |
| Cash/Share | |
| Dividend Est | |
| Dividend TTM | |
| Dividend Ex-Date | |
| Employees | |
| Moving Avg 20days | |
| Moving Avg 50days | |
| Moving Avg 200days | |
| Shares Outstanding | |
| Earnings Date | |
| Inst. Ownership |
| Price/Earnings | |
| Forwad P/E | |
| PE Growth | |
| Price/Sales | |
| Price/Book | |
| Price/Cash | |
| Price/FCF | |
| Quick Ratio | |
| Current Ratio | |
| Debt/Equity | |
| Return on Assets | |
| Return on Equity | |
| Return on Investment | |
| Gross Margin | |
| Ops Margin | |
| Profit Margin | |
| RSI | |
| BETA(β) | |
| From 52week Low | |
| From 52week High |
| EPS | |
| EPS next Year | |
| EPS next Qtr | |
| EPS this Year | |
| EPS next 5 Year | |
| EPS past 5 Year | |
| Sales past 5 Year | |
| EPS Y/Y | |
| Sales Y/Y | |
| EPS Q/Q | |
| Sales Q/Q | |
| Sales Surprise | |
| EPS Surprise | |
| ATR(14) | |
| Perf Week | |
| Perf Month | |
| Perf Quarter | |
| Perf Year | |
| Perf YTD | |
| Target Price |
AryaFin Engine© - An AI FinTech Venture - 2024-26 Disclaimer